Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.

Détails

ID Serval
serval:BIB_D1BDDC7D96C0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.
Périodique
Nature communications
Auteur⸱e⸱s
Koya J., Tanigawa T., Mizuno K., Kim H., Ito Y., Yuasa M., Yamaguchi K., Kogure Y., Saito Y., Shingaki S., Tabata M., Murakami K., Chiba K., Okada A., Shiraishi Y., Marouf A., Liévin R., Chaubard S., Jaccard A., Hermine O., de Leval L., Tournilhac O., Damaj G., Gaulard P., Couronné L., Yasui T., Nakashima K., Miyoshi H., Ohshima K., Kataoka K.
ISSN
2041-1723 (Electronic)
ISSN-L
2041-1723
Statut éditorial
Publié
Date de publication
22/10/2024
Peer-reviewed
Oui
Volume
15
Numéro
1
Pages
9106
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands. Both human and murine NK-cell lymphomas express tissue-resident markers, suggesting tissue-resident NK cells as their cell-of-origin. Murine NK-cell lymphomas show recurrent Myc amplifications and upregulation of MYC target gene signatures. EBV-encoded latent membrane protein 1 expression accelerates NK-cell lymphomagenesis and causes diverse microenvironmental changes, particularly myeloid propagation, through interferon-γ signaling. In turn, myeloid cells support tumor cells via CXCL16-CXCR6 signaling and its inhibition is effective against NK-cell tumors in vivo. Remarkably, KLRG1-expressing cells expand in the tumor and are capable of repopulating tumors in secondary recipients. Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors. Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.
Mots-clé
Animals, Killer Cells, Natural/immunology, Killer Cells, Natural/metabolism, Mice, Tumor Microenvironment/immunology, Lymphoma, Extranodal NK-T-Cell/genetics, Lymphoma, Extranodal NK-T-Cell/metabolism, Lymphoma, Extranodal NK-T-Cell/virology, Lymphoma, Extranodal NK-T-Cell/pathology, Humans, Proto-Oncogene Proteins c-myc/metabolism, Proto-Oncogene Proteins c-myc/genetics, Tumor Suppressor Protein p53/metabolism, Tumor Suppressor Protein p53/genetics, Mice, Knockout, Disease Models, Animal, Interferon-gamma/metabolism, Receptors, CXCR6/metabolism, Receptors, CXCR6/genetics, Chemokine CXCL16/metabolism, Chemokine CXCL16/genetics, Herpesvirus 4, Human, Gene Expression Regulation, Neoplastic, Signal Transduction, Salivary Glands/pathology, Salivary Glands/metabolism, Myeloid Cells/metabolism, Cell Line, Tumor, Mice, Inbred C57BL
Pubmed
Open Access
Oui
Création de la notice
25/10/2024 8:28
Dernière modification de la notice
25/10/2024 14:58
Données d'usage